多发性硬化共病与诊断延迟及死亡率增加相关
这项丹麦全国人群队列研究纳入1980至2005年间首发症状的多发性硬化(MS)患者8947例,发现脑血管、心血管、肺、糖尿病和癌症共病与诊断延迟相关,而精神、脑血管、心血管、肺、糖尿病、癌症和帕金森病共病与死亡率升高相关。
要点
- 心血管共病使MS诊断延迟的比值比达4.04。
- 癌症共病与MS死亡风险升高相关,风险比3.51。
- 对已有慢性病者出现新神经症状应警惕并评估MS。
核心结论
- MS患者合并慢性共病与诊断延迟及死亡率增加相关。
研究设计与样本
- 基于丹麦全国人群的队列研究,纳入1980至2005年间首发MS症状的8947例患者。
- 采用多项逻辑回归分析诊断时间,Cox回归分析死亡率。
主要发现
- 诊断延迟的比值比:脑血管共病2.01(1.44-2.80),心血管共病4.04(2.78-5.87),肺共病1.93(1.42-2.62),糖尿病共病1.78(1.04-3.06),癌症共病2.10(1.20-3.67)。
- 死亡风险比:精神共病2.42(1.67-3.01),脑血管共病2.47(2.05-2.79),心血管共病1.68(1.39-2.03),肺共病1.23(1.01-1.50),糖尿病共病1.39(1.05-1.85),癌症共病3.51(2.94-4.19),帕金森病共病2.85(1.34-6.06)。
临床怎么用
- 对已有慢性病的患者出现新神经系统症状时,应提高警惕并考虑MS评估。
- MS患者应优化共病治疗以改善预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS. METHODS: We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic regression. To investigate mortality, we used Cox regression with time-dependent covariates, following study participants from clinical MS onset until endpoint (death) or to the end of the study, censuring at emigration. RESULTS: We identified 8,947 individuals with clinical onset of MS between 1980 and 2005. In the study of time of diagnosis, we found statistically significant odds ratios for longer diagnostic delays with cerebrovascular comorbidity (2.01 [1.44-2.80]; <0.0005), cardiovascular comorbidity (4.04 [2.78-5.87]; <0.0005), lung comorbidity (1.93 [1.42-2.62]; <0.0005), diabetes comorbidity (1.78 [1.04-3.06]; 0.035), and cancer comorbidity (2.10 [1.20-3.67]; 0.009). In the mortality study, we found higher hazard ratios with psychiatric comorbidity (2.42 [1.67-3.01]; <0.0005), cerebrovascular comorbidity (2.47 [2.05-2.79]; <0.0005), cardiovascular comorbidity (1.68 [1.39-2.03]; <0.0005), lung comorbidity (1.23 [1.01-1.50]; 0.036), diabetes comorbidity (1.39 [1.05-1.85]; 0.021), cancer comorbidity (3.51 [2.94-4.19]; <0.0005), and Parkinson disease comorbidity (2.85 [1.34-6.06]; 0.007). CONCLUSIONS: An increased awareness of both the necessity of neurologic evaluation of new neurologic symptoms in persons with preexisting chronic disease and of optimum treatment of comorbidity in MS is critical.
引用
- Thormann A, Sørensen PS, Koch-Henriksen N, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017. PMID: 28931645. doi:10.1212/WNL.0000000000004508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。